Stock leaps in early trade, but to justify its huge valuation the technology might have to improve.
The sequencing group’s $8bn deal to recapture Grail leaves shareholders unimpressed.
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
Even if the sequencing giant doesn't suffer in the short term from the death of its bid for Pacbio, long-read tech is nipping at its heels.
Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.
Can the company's $1.5bn valuation be justified when last year it took just $23.5m in orders?